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Tjáhtje le iellem 
 
“Water is life” in the Lule Sami language 
Spoken by approximately 500 in the world. 
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 ABSTRACT 
 
Mathematical modelling of clinical applications in fluid therapy 
 
 
 
Background: This thesis presents a new application of fluid kinetic analysis using mathematical tools to evaluate fluid 
therapy problems. Several models were developed to mathematically handle fluid distribution concerning bleeding and 
anaesthesia, arterio-venous differences in plasma dilution, peripheral fluid accumulation and differences in fluid distribution 
among young and elderly patients. Non-linear regression models were used to fit equations to sampled haemoglobin data. 
Methods: I: Six chronically instrumented sheep were subjected to four randomly ordered experiments while conscious or 
during anesthesia with isoflurane. After plasma volume measurement 15% or 45% of the blood volume was withdrawn. To 
quantify transcapillary refill, mass balance and kinetic calculations utilized repeated measurements of haemoglobin 
concentration. II: Fifteen volunteers received an intravenous (iv) infusion of 15 mL/kg of lactated Ringer’s solution during 
10 min. Simultaneous arterial and venous blood haemoglobin (Hb) samples were obtained and Hb concentrations measured. 
III: Ten healthy female non-pregnant volunteers participated. The protocol included an infusion of acetated Ringer’s 
solution, 25 ml/kg over 30 minutes. Blood samples were repeatedly. A standard bladder catheter was continuously 
monitoring urine excretion. Plasma dilution, peripheral accumulation and urine output were modelled simultaneously. IV: 
Twenty four volunteers participated. Two age groups, a young group (age 18-25) and an elderly group (age 70-90) were 
formed. On separate occasions, the subjects in both groups were given a crystalloid 25 mg/ml glucose solution, either orally 
(ORAL) or intravenously (IV) in a crossover design with at least two weeks in between. On each occasion, the subjects got 7 
ml/kg of the crystalloid solution during 15 minutes.  
Results: I: After either normotensive or hypotensive hemorrhage, transcapillary refill occurred more rapidly during the first 
40 min than during the next 140 min (p < 0.001). In conscious sheep, at 180 min, 57% and 42% of the bled volume had been 
restored after normotensive and hypotensive hemorrhage, respectively, in contrast to only 13% and 27% (p < 0.001) in 
isoflurane-anesthetized sheep. Using parameters derived from kinetic analysis, simulations illustrate that both the hydrostatic 
and colloid osmotic forces are weaker in the presence of isoflurane than in the awake state. 
II: The AV difference in plasma dilution was only positive during the infusion and for 2.5 min thereafter, which represents 
the period of net flow of fluid from plasma to tissue. Kinetic analysis showed that volume expansion of the peripheral fluid 
space began to decrease 14 min (arterial blood) and 20 min (venous blood) after the infusion ended.  
III: Maximum urinary output rate was found to be 19 (13 – 31) ml/min. The subjects were likely to accumulate three times as 
much of the infused fluid peripherally as centrally; Elimination efficacy, Eeff, was 24 (5 – 35) and the basal elimination kb was 
1.11 (0.28 – 2.90). The total time delay Ttot of urinary output was estimated to 17 (11 - 31) min.  
IV: The lag-time of glucose given orally was estimated to be 17 (8 – 25) min for the younger group and 18 (13 – 22) min for 
the elderly. For fluid, the lag-time was estimated to 29 (21 - 34) min for the younger and 25 (16 – 39) min for the elderly.  
Conclusions: Final conclusion is that mathematical modelling of clinical applications can be done in several different clinical 
settings and will improve the understanding of fluid distribution. It is possible to continuously model fluid behaviour in the 
body as seen in Papers II-III. This should enhance the understanding of accumulating oedema in the body which is an 
apparent problem for all clinicians.  
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TBW Total Body Water (ml) 
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H Height (m) 
ECF Extracellular Fluid (ml) 
ICF Intracellular Fluid (ml) 
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EVF Erythrocyte Volume Fraction (ml) 
ECV Erythrocyte Cell Volume (ml) 
PV Plasma Volume (ml)  
Hct Hematocrit 
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2 SUMMARY 
 
 
The main objective of this thesis is to develop the understanding of fluid therapy by the use of 
applied mathematics and to find appropriate clinical characteristics and physiological 
explanations by mathematical models.  
 
The theoretical platform of fluid therapy has not widened as much as other clinical scientific 
fields [5]. Very much of fluid therapy is based on tradition and rules-of-thumb. One main 
issue is that a number of variables, which are essential to make a deeper assessment of the 
fluid status of a patient, cannot be measured accurately without significant intrusion in clinical 
practice. 
 
Even though intravenous fluids should be classified as drugs since they are given in large 
amounts daily in hospitals and have great impact on outcomes of patients, they are commonly 
regarded merely as technical aids. Although fluids are part of daily clinical practice the 
scientific evidence behind their applications is weak. Therefore, clinicians are reluctant to 
change their routine practice [6]. 
 
However, the need for fluid resuscitation, treatment of dehydration and hypovolemia, and for 
correcting various pathological states that inflicts negatively on the outcome, acid-base levels, 
the microvascular perfusion, the oxygen transport and the osmotic balance, is pertinent [7]. 
 
Therefore there is need of more solid evidence for fluid applications in clinical practice.  
 
The main conclusion of the thesis is that mathematical modelling may contribute to a better 
understanding of fluid distribution and eventually form more solid theoretical concepts.  
  
 
 
 
 3 BODY FLUID DYNAMICS – A BRIEF 
INTRODUCTION 
 
 
 
A cold water spring in the north of Sweden 
 
 
Water is one of the cornerstones of life. The water serves as a solute to dissolve other solutes 
and it transport nutrients, oxygen and other necessary compounds within and between cells 
[8]. Furthermore, water dissolved ions creates the cell membrane potential, which is crucial 
for almost all transport of solutes across the cell membrane [9]. Water is also a necessary 
component in almost all biochemical processes such as cell respiration and photosynthesis 
[10]. In fact, science today cannot predict or even imagine any life forms in the universe 
without the presence of water, even if there are some exotic guesses. 
 
An adequate fluid and salt balance is therefore of a major importance for almost all basic and 
critical body processes, ranging from physiological functions to basic cell processes [9]. Even 
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a small perturbation of this balance will affect the well-being and even short-term survival of 
any living organism on earth. 
 
3.1 TOTAL BODY WATER 
 
The total body water (TBW) is the amount of water in the whole body, distributed through 
several compartments, commonly divided into the extracellular fluid space (ECF) and the 
intracellular fluid space (ICF) [10]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The fluid distribution in the body 
 
  
The turnover rate of water for TBW varies greatly betweens individuals, and it depends 
highly on activity, temperature etc. However, a common estimation for adults, in a temperate 
environment, is that about 2 L/day is needed, corresponding to 5-10% in turnover rate of the 
TBW [11].  
 
Our daily consumption of water is through oral intake, but a small amount of water is also 
produced within the cells as a result of the citric acid cycle. Water losses are through skin, 
respiration, urine, faeces and sweat, see Figure 2 as an example [10]. The basal loss of fluid 
per minute is about 0.5 - 1.5 ml/min for an average adult [12], an important parameter to 
consider in almost all clinical situations [13]. 
TBW ~ 0.60 · BW 
ECF ~ 0.2 · BW ICF ~ 0.4 · BW 
PV
 ~
 0
.0
5 
· B
W
 
IV
 ~
 0
.1
5 
· B
W
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Figure 2.  Example of a TBW daily turnover from [10]. 
 
 
Loss of only 5% of TBW, which corresponds to approximately 2.5 L for an adult, results in 
clinical consequences [14] while a loss of 15% of TBW is a life-threatening condition. 
 
Dilution methods 
 
From the trivial relationship 
 
C = N / V, concentration = number / volume,  
 
any one of these quantities can be determined when two are known. By adding a known 
number Nex (or a known mass) of an exogenous compound1, and then measuring the 
concentration C, we can easily compute the volume V. See Figure 3. 
 
                                                 
1 Compounds not existing by natural in the body 
Respiration (-350 ml) 
Skin (-350 ml) 
Urine (-1400 ml) 
Faeces (-100 ml) 
Sweat (-100 ml) 
Oral intake (+2100 ml) 
Metabolism (+200 ml) 
TBW
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Figure 3. Basic principle of the dilution technique 
 
 
When adding an endogenous2 compound, we must first determine the endogenous 
concentration Cen. After mixing, the concentration will be 
 
en
ex
en
exenex
CC
N
VC
V
N
V
NN
C −=→+=
+= , 
 
where Nen is the amount of compound that already resides within the volume V, and  
 
Cen = Nen/V. 
 
Estimating TBW 
 
TBW may be estimated by anthropometric3 formulae, commonly validated from tracer 
dilution methods. Anthropometric predictions of various physiological properties may depend 
                                                 
2 Compounds that already exists in the body – such as glucose 
3 Anthropometry 
1. Add Nex tracers 
2. Wait until mixed
3. Sample concentration C 
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on height, weight, age, gender, race etc resulting in various degrees agreement of agreement 
at the level of individuals [15-17]. For example  
 
TBW (females) = -2.097 + 0.1069 · H + 0.2466 · BW, 
 
where H is height (cm) and BW is bodyweight (kg). The error could be substantial [17]. This 
equation does not take into account that the TBW decreases by age [15]. The amount of body 
fat also influence the TBW: the more fat, the less water [18].  
 
Nevertheless, anthropometric models can be important tools when building models or 
simulators, in order to verify the coupling to physiology of the model or to explore fluid 
management in vitro4. 
 
Measuring TBW 
 
The gold standard when measuring TBW is the value determined using isotope dilution 
techniques, preferable non-radioactive isotopes. The stable water isotopes used are 2H2O and 
H218O, and the precision can be as high as 1 %, in variation [11, 19]. However, the method 
used is not clinically feasible due to its complex experimental set-up and the mixing time 
required for the tracer [20]. 
 
Bioelectrical impedance analysis is another method to estimate TBW. By considering the 
body as a cylindrical isotropic conductor, and applying an electrical signal along the body, it 
is possible to estimate the amount of water residing within this conductor when considering 
the composition. However, although simple, quick and cheap to use, there are many sources 
of error, which may have an impact on the quality of the final result [21]. 
 
                                                 
4 In vitro – experiments outside the body, in an artificial environment. In vivo – experiment inside the body. 
Peter M. Rodhe 2010 18
Intracellular fluid space 
 
The intracellular fluid space (ICF) is the largest fluid space, and has a volume about twice that 
of the ECF. Although distributed over the 10-100 trillion5 cells in the human body, each one 
of which has a unique composition, the ICF is still considered as a single homogenous fluid 
compartment. The reason for this is the almost identical properties of the cell membranes 
among all cells, designed to maintain the osmotic equilibrium between the ICF and the ECF 
[9].  
 
3.2 EXTRACELLULAR FLUID SPACE 
 
The fluid residing outside cells is commonly referred as being in the extracellular fluid space6, 
ECF. This fluid can be found in blood plasma, the interstitial space7, the gastrointestinal 
tract8, the cerebrospinal space9 and the intraocular space10. About 20 % of the body fluid 
resides in the ECF space [10]. 
 
Determining the volume of ECF 
 
There are many tracers that can be used to measure the volume of ECF, the most commonly 
used of which is the bromide ion. The drawbacks of using bromide as a dilution tracer is that 
it requires a long mixing time, and that bromide does not distribute equally through the ECF 
[11, 22]. 
 
                                                 
5 An estimation of, even in the variation of one billion, the number of cells in the human body is incalculable. 
6 Extracellular fluid space or compartment or volume 
7 Or the interstitium, the space between tissue cells 
8 Colon and the small intestines 
9 Fluid in the brain and the spinal cord 
10 Fluid within the eye 
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Interstitial fluid 
 
The interstitium consists of a gel-type composition of proteoglycan filaments and collagen 
fibers. Fluid does not pass easily across this gel, but it still serves as an active and fast 
transport layer for solutes and water into cells. Transport takes place through diffusion rather 
than convection [23].  The interstitial matrix also contains rivulets and vesicles of “free fluid”. 
In a normal state, the volume of this free fluid is negligible compared to the interstitium as a 
whole, but these fluid spaces can become enlarged in oedema [24]. 
 
3.3 BLOOD VOLUME  
 
The blood volume consists of two parts, the volume of erythrocytes11 (ECV) and the volume 
of plasma (PV). The total blood volume (TBV) is distributed between the systemic 
circulation12 and the pulmonary circulation13. About 84 % of the blood is contained in the 
systemic circulation [10]. 
 
 
 
Figure 4. The distribution of blood in the circulation [10] 
 
                                                 
11 Red blood cells 
12 The peripheral circulation, to tissues, most of the organs and to the brain 
13 Circulation to and from the lungs 
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From figure 4, we may see that the veins are the main storage of blood. Even though the 
capillaries contain a small fraction of the entire blood volume, the cross-sectional area of the 
capillaries is about 30 – 1000 times larger than the cross-sectional area of any part of the 
veins or arteries [10].  
 
Prediction of blood volume 
 
Some anthropometric formulae have been developed through the years. One of those is the 
empirical formula developed by Nadler et al. [25].  
 
TBV (Men) = (0.6041 + 0.03219 · BW + 0.3669 · L3) · 1000 
TBV (Women) = (0.1833 + 0.03308 · BW + 0.3561 · L3) · 1000 
 
This formula is extensively used as a reference in work II-IV. 
 
Erythrocytes and Haemoglobin 
 
Each erythrocyte cell in the human body, contains around 300 million molecules of 
haemoglobin. The molecule itself is formed by polypeptide chains, the globulins. When 
synthesized by the ribosomes, they form the haemoglobin chain in which four of those bind 
together into the haemoglobin molecule (Hb). These four substructures contain an iron atom 
that is capable to bind one oxygen molecule. Thus, one erythrocyte cell, in theory, may 
transport over a billion oxygen molecules at the same time [10].  
 
 Erythrocytes as scanned by an electron micrograph [26] 
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The hematocrit 
 
An important parameter is the erythrocyte volume fraction (EVF) of the blood, more 
commonly known as hematocrit (Hct). This parameter is historically determined by packing 
red blood cells through centrifugation, which separates the red blood cells from the blood 
plasma, see Figure 5. In a modern clinical laboratory, however, the Hct is measured by other 
methods14. The normal value ranges from 30 % - 50 %.   
 
 
 
Figure 5. Separation of plasma, erythrocytes and white blood cells. The fraction of 
erythrocytes in the sample tube is the Hct. 
 
 
The Hct fraction is extensively used when estimating fluid status, plasma content versus 
erythrocytes. Though, there is a consensus, that the estimated Hct from lab is overestimated 
due to trapped plasma15 [27]. Experimentally determined Hct values, therefore, are sometimes 
corrected by 0.9 before being used in models, as discussed in paper II [2]. 
 
                                                 
14 Impedance plethysmography. 
15 Trapped plasma – plasma fluid between packed erythrocytes. 
Erythrocytes 
Leukocytes and Thrombocytes 
Plasma 
H
ct
 
1 
- H
ct
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Measuring ECV and PV 
 
The volume of erythrocytes (ECV) may be determined by isotope-labeling erythrocytes with 
51Cr and 99mTc for example [28] but there are other non-radioactive methods, such as labelling 
erythrocytes with sodium fluorescein [29].  
 
The plasma volume (PV) may be determined by isotope-labeled albumin. The drawback of 
this method, besides the radioactivity, is that albumin leaks through the capillaries into the 
interstitial fluid, which gives an overestimation of the distribution volume. The isotope used 
to mark albumin is 125I. The precision is said to be 3 % [30]. Other commonly used agents are 
Evans Blue, a dye that binds to albumin , and indocyanine green (ICG), a dye that binds to 
globulin [31]. The advantage of these methods is that they are non-radioactive, although the 
do suffer from other drawbacks. Still, the precision may be as high as that obtained using 125I 
[20]. 
 
If either ECV or PV is known, the other may be computed from Hct by the relationship 
 
ECV
PVECVHCT += . 
 
In Paper I [1], ICG was used initially to measure the plasma volume. Unfortunately, ICG is 
difficult to obtain, and stocks of ICG in the US were empty at the time, something that 
illustrates the problem of measuring the plasma volume by this method. 
 
Hb as a diluting tracer 
 
In paper II, we investigated the use of haemoglobin as a tracer and compared Hb 
concentrations in venous samples with arterial Hb concentration during a crystalloid infusion. 
Haemoglobin should be ideal as a tracer when estimating blood volume, because of its 
incapability to penetrate the capillary wall. 
 
Let us start by the relation 
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XHb = VB · CHb, 
 
where VB (ml) is the initial total blood volume and CHb is the haemoglobin concentration 
(mmol/ml). Hence, the plasma volume at baseline, Vp (ml) may be computed from the 
hematocrit level:  
 
Vp = VB · (1 - Hct). 
 
The plasma volume, as a function of time, vp(t) can then be obtained from 
 
( ))(1
)(
tHct
tC
Xv
Hb
Hb
p −⋅= . 
 
Now, if we consider the vascular volume VB, to be a completely closed space, we can easily 
compute the plasma volume by infusing a known amount Vi of crystalloid solution. 
 
 
 
 
 
   
 
 
 
 
Figure 6. Infusion of fluid into a closed space with the volume VB and concentration CHb at 
t = 0. After the infusion and mixing time, at time t = T, we measure the 
concentration CHb(T).  
 
Haemoglobin 
VB VB + Vi 
CHb(T) 
CHb(0) 
T 
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In this trivial case, the plasma volume is given by 
 
( )
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
−⋅=
1
)(
)0(
)0(1
TC
C
HctVV
Hb
Hb
ip . 
 
3.4 FLUID BALANCE 
 
Body fluid content 
 
The body fluids contain a wide range of solutes: proteins, glucose and ions – a chemical soup 
forming a delicate balance regarding acid-base levels and osmotic relationships. This balance 
is called the fluid homeostasis the concept of the milieu interieur that was created by Claude 
Bernard (1813 – 1878) [5]. In presence of a semi-permeable membrane16, a pressure will arise 
if there is an osmotic gradient through the membrane. The substances in the different 
compartments are illustrated in Table 1. 
 
Substance Plasma Interstitial Intracellular
Na+ 143.0 140.0 14.0
K+ 4.2 4.0 140.0
Cl- 108.0 108.0 4.0
HCO3- 24.0 28.3 10.0
Glucose 5.6 5.6 0
Urea 4.0 4.0 4.0
Others 14.0 11.9 130.2
Total mOsm/litre 302.8 301.8 302.2
OA 282.5 281.3 281.3
 
Table 1. The constituents of the body fluids (mOsm/litre). OA is the corrected osmolar activity 
(mOsm/litre). 
 
                                                 
16 A membrane permeable to only some solutes and water, which separates the non-permeable solutes from each 
other 
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The final osmolar activity OA, depends on each substance. This osmolar correction arises 
when electrostatic forces from dissolved ions are present, which may lower or raise the 
osmolar activity for a specific solute. The potential osmotic pressure is given by 
 
RTOA ⋅=Π , 
 
where R is the gas constant (0.062364  L mmHg K-1 mmol-1) and T the absolute temperature.  
 
The osmotic balance plays an important role in the fluid distribution, especially between ICF 
and ECF, and in the filtration process along the capillary bed. The capillary walls are 
permeable for most of the solutes in the plasma, but larger proteins, such as albumin, do not 
easily penetrate the membranes into the interstitial space. Thus, an osmotic gradient will be 
present between the plasma and the interstitium. This potential, or the oncotic pressure, 
exerted by a specific protein X, is given by 
 
( )IXpXXX RT ,, ProtProt)Prot( −⋅⋅=ΔΠ σ , 
 
where σX is the reflection coefficient for the specific protein combined with the semi-
permeable membrane, and ProtX,p and ProtX,I  are the osmolar content in plasma and 
interstitium respectively (mOsm/litre). The reflection coefficient is typically dependant on the 
size of the molecule: the larger molecule, the larger the σX and the lesser size of pores of the 
membrane, the larger the reflection coefficient [10]. 
 
In Paper I, we used the relationship between oncotic gradients and hydrostatic pressure to 
quantify changes of the filtration process during bleeding. The Starling equation states that the 
filtration flow Jv is given by 
 
( ) ( )( )IpIpv PP = kJ −−Π−Π⋅⋅ σ , 
 
where P is the hydrostatic pressure in the capillaries (Pp) and the interstitium (PI)  (mmHg), 
and k is a fluid filtration coefficient, sometimes referred as the capillary hydraulic 
conductivity [32]. 
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Figure 7. Schematic diagram of the interstitium. From the capillaries below, fluid 
filters through the capillary wall and enters the interstitial gel. Solutes and 
fluid are exchanged with cells, and any superfluous fluid and proteins are 
pumped away through the terminal lymphatic. Lymphology 11:128-132, 
1978. Permission from the author. 
 
 
Fluid feed-back system 
 
The balance of salt and water, is governed by a complex feedback system that involves 
hormones: ADH (antidiuretic hormone), RAS (renin-angiotensin), ANP (atriopeptin), ALD 
(aldosterone), ANG II (angiotensin II) and specialised cell receptors; baroreceptors and 
osmoreceptors, see Figure 8.  
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Figure 8. Overview of salt and water regulation, cf. [33] 
 
3.5 CIRCULATION AND FILTRATION OF BODY FLUIDS 
 
Until 1628, the liver was thought to be as an inexhaustible reservoir of blood. In the liver, 
food was transformed into blood, which then streamed into the right side of the heart where it 
was heated and then pumped out to the limbs where it was consumed. Considering our 
knowledge today, producing 5 litres of blood per minute, would be a quite remarkable exploit 
by a single organ. However, William Harvey took one step forward in mankind’s 
understanding of the blood through his dissertation De Motu Cordis [34]. He could not, 
however, explain how the blood passes from the arteries to the veins. It was not until the 
invention of the microscope that the existence of the capillaries and their function was 
understood [20].  
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Blood pressure control 
 
The blood pressure is controlled by either parasympathetic stimulation17 or sympathetic 
stimulation18, which adjust oxygen delivery and the distribution of fluid between the different 
fluid compartments.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. The parasympathetic (PS) and the sympathetic stimulation (SS) of blood 
pressure (BP). Through regulation of heart rate (HR), cardiac output (CO), 
stroke volume (SV), venous return, systemic vascular resistance (SVR) and left 
ventricular diastolic volume (LVEDV). 
 
 
The pressure/flow relation in the human body is given by, using the abbreviations from Figure 
9, 
 
BP = CO · SVR = (SV · HR) · SVR. 
 
BP is also referred as mean arterial pressure, MAP, computed as 
 
MAP = 
3
2 SPDP +⋅ , 
                                                 
17 The activity of the nervous system during rest 
18 The activity of the nervous system during stress 
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where SP is the systolic blood pressure and DP is the diastolic blood pressure. The systolic 
pressure is the maximum arterial pressure reached during the heart’s systolic phase – “the 
pump out”. The pressure then drops to the diastolic pressure, before being raised again. See 
Figure 10. 
 
 
 
Figure 10. Principal sketch over the pressure fall (mmHg) through the systemic circulation, 
cf. [10] 
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Macro-circulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Overview of the circulation and the distribution of cardiac output over 
various organs during rest, cf. [10]. 
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Micro-circulation  
 
The micro-circulation, or microvascular fluid exchange, takes place in the capillary bed, 
where the exchange of nutrients, blood gases and water takes place. See Figure 12. 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Sketch of the microcirculation through the capillary bed. The inflow of blood 
(solid arrows) into the capillaries is controlled by the sphincters. The blood may 
bypass the capillaries through a shunt (dashed line). 
 
 
Figure 12 shows the role of the pre-capillary sphincters. By controlling these smooth muscles, 
the inflow into the capillaries may be adjusted and even cut-off completely. Post capillary 
sphincters work in close relationship with pre capillary sphincters. Paper II refers to A-V 
shunts, through which blood passes the capillary bed, when the pre-capillary sphincters are 
closed.  
 
The property of the capillaries, and their filtrating abilities, differ vastly between organs and 
tissue. As an example, the reflection coefficient of albumin in different regions varies from 0 
(spleen), 0.9 (skeletal muscle) to 1.0 (brain) [20].  
 
Thus, in general, the behaviour of the capillary wall, which is, as discussed earlier, a semi-
permeable membrane, is governed by micropores. These are usually divided into three 
categories – aquaporins, small interendothelial pores and large pores [35]. The large pores are 
permeable to all solutes. These are less frequent than the small pores, but may arise when the 
Arteriole 
Venule 
Pre-capillary sphincters Capillaries 
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capillary wall is disrupted due to inflammation or other pathological states. The aquaporins 
are permeable only to water.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The capillary process over a distance x through the capillaries. Solutes, water 
and proteins diffuses through the small pores between the endothelial cells.  
 
 
Figure 13 shows the basic principles of filtration. The blood flows from left to right, due to 
the pressure gradient PA – PV. Water and small solutes tunnel through the small pores and 
diffuse through the interstitial gel. However, amounts of some proteins, such as albumin, leak 
through the small pores. Eventually, any excess water, superfluous proteins and other solvents 
are pumped away through the lymphatic ducts. The net filtration ΔJ of one capillary route 
may be computed from: 
 
( ) ( )( )∫ −−Π−Π⋅⋅Δ V
A
IpIp dxxPxPxxkJ = )()()()(σ . 
 
The interstitial hydrostatic and oncotic pressure is sometimes considered to be constant 
through the capillaries when modelling the phenomena [36].  
 
The total net filtration of the body (estimated to 2 ml/min [10]) is eventually transported back 
through the lymphatic ducts into the veins. 
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4 CLINICAL PERSPECTIVES 
 
 
 
Jean Baptiste Denis (1620 – 1704)  
The first successful blood transfusion 1667 
 
 
4.1 INTRODUCTION 
 
The knowledge of the necessity of an adequate circulation is probably as old as mankind. The 
first successful transfusion of blood is said to have been carried out 1667, when a physician,  
infused blood from sheep to a hypovolemic man. Naturally, only a few of these treatments 
were successful, which forced the Royal Society of London, the French Parliament and the 
Church of Rome to prohibit further experiments. Not until the end of 19th century did blood 
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transfusion and fluid infusion become increasingly safer due to awareness of the blood 
constituents, the capillary mechanisms and the need of sterile equipment [20]. 
 
An adequate circulation and fluid homeostasis is of a critical importance in a wide range of 
clinical applications, especially during surgery. Virtually all surgical patients receive 
intravenously administered fluid during their hospital stay [20].  
 
4.2 DEHYDRATION 
 
Symptoms 
 
Early symptoms of dehydration include a dry mouth, low urinary output, absence of tears, 
tiredness, sunken eyes, dark and concentrated urine and markedly increased skin turgor [38].  
 
Other more severe symptoms will arise due to electrolyte imbalances, an impaired perfusion 
of important organs and impaired cardiovascular capabilities. These symptoms may be non-
specific – weakness, dizziness, fatigue, chest pain, confusion or muscle cramps. If the 
dehydration gets worse, the condition may lead to hypovolemic shock, organ failure and 
ultimately death [39]. 
 
 
 
 
 
 
 
 
 
 
Figure 14. Three common states of dehydration. Salt and water move from the optimal 
homeostasis of ECF and ICF into a dehydrated state (dotted areas).  
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Figure 14 shows three different stages in dehydration are exemplified. Dehydration may arise 
from several pathological states including diarrhea, impaired renal function, reduced sensation 
of thirst, and fever.  
 
Children  
 
The daily turnover of TBW for an average adult, as previously stated, was about 5-10 % of 
TBW which corresponds to 35-70 ml/kg and day. The turnover rate is higher in infants: 160 
ml/kg and day (3 months), 100 ml/kg and day (12 months) and 65 ml/kg (3 years) and day 
[40]. Because of the renal and cardiovascular immaturity in infants, and the higher turnover, 
the body fluid homeostasis is much more critical for paediatric patients than it is for adults 
[41]. Thus, dehydration of infants is an acute syndrome that has to be treated immediately. 
Elderly 
 
Dehydration is a significant problem for the elderly population as the body composition of 
water changes with age towards a drier state [16]. This physiology in combination with slight 
hypoaldosteronism19, reduced sensation of thirst, impaired ability to concentrate urine and, in 
many cases, forgetfulness to drink can lead to significant dehydration and a troublesome 
situation for patients and caregivers. The consequences of dehydration are several and 
sometimes severe: vertigo and imbalance leading to falls, urinary- and respiratory infections 
with or without septicaemia20, delirium, renal failure and increased risk for medication 
toxicity. Elderly with co-morbidities are at an increased risk for repeated hospitalizations [42-
44]. Perhaps the most significant consequence of dehydration is an increased mortality among 
hospitalized older adults [45].  
 
4.3 HYPERHYDRATION 
 
Hyperhydration may occur due to pathophysiology or an excessive fluid administration. If the 
capillary filtration increases, due to increased hydrostatic capillary pressure or an increased 
                                                 
19 Decreased levels of the hormone aldosterone 
20 Systemic inflammatory response syndrome (SIRS) or blood poisining 
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permeability of the capillary walls, the lymphatic system may not be able to remove excess 
fluid. 
 
This situation may arise during congestive heart failure, where the venous return is poor or as 
a result of lowered muscular activity (due to hospitalization for example), which is needed for 
the lymphatic drainage to work adequately. Other pathophysiological causes are kidney 
failure (which causes water retention), famine, burns, septicaemia etc., all of which are 
conditions that may increase the local filtration rate and re-absorption in the capillaries. 
 
Eventually, overhydration leads to peripheral oedemas; and in worst cases: pulmonary 
oedemas, which is a life-threatening condition [46].  
 
Symptoms vary and include anxiety, confusion, headache and nausea may as a result of 
excess fluid exerting a higher pressure on the brain.  
 
 
 
 
 
Edema 
 
 
 
Figure 15. Three stages of hyperhydration [47] 
 
 
Figure 15 shows the main pathophysiological states of hyperhydration.  
 
4.4 BLEEDING 
 
Loss of blood volume due to bleeding stimulates virtually the same process of defending the 
volume as dehydration does. Symptoms of bleeding include decreased blood pressure, 
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increased heart rate, reduced urinary output, pallor with cold sweat and thirst [33]. This state 
is called hemorrhagic shock.  
 
Several important responses, including hormonal responses, which eventually restore the 
circulating volume, are stimulated. The volume, however, can only be restored if the bleeding 
is stopped.  
 
Firstly, the filtration decreases when the capillary hydrostatic pressure decreases, leading to a 
fast drainage of protein-free fluid from the interstitium to the plasma volume. As much as 
75% of the blood volume loss is restored due to this effect within an hour [48].  
 
We show in Paper I that this effect is significantly reduced during isoflurane anaesthesia. The 
starling equation enabled us to quantify this effect by separating the mean hydrostatic 
capillary pressure and the mean oncotic effect of transcapillary refill.  
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5 MATERIALS AND METHODS 
 
 
 
Common sampling sites of clinical outputs relevant to assess hydration and 
hemodynamical status. I - Invasive21 and NI – Non-invasive. From 
“Sleeping Venus” by the Italian painter Giorgone (1477-1510). 
 
 
In this section I will go through the materials and methods used in this thesis. In Table 2 we 
have listed some of the methods. 
 
 
 
 
 
 
                                                 
21 Invasive – within the body 
Bioimpedance (NI) 
Venous line (I) 
Oesophageal Doppler (I) 
Cuff (NI) 
Urinary catheter (I) 
Bladderscan (NI) 
Electrocardiography (NI) 
Pulse oximeter (NI) 
Arterial line (I) 
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 Parameters Time to result 
Arterial/Venous line Glucose, Hb, Hct, pH, hormones, ions,… 1 min – several hours 
Electrocardiography Heart variability, heart rate < 1 min 
Bladderscan Urine volume < 1 min 
Cuff Blood pressure < 1 min 
Oesophageal Doppler Cardiac output index < 10 min 
Pulse oximeter Oxygenation < 1 min 
Bioimpedance Total body water < 10 min  
Urinary catheter Urine output, urine content 1 min – several hours 
 
Table 2. Clinical output of various parameters. 
 
Hemodynamics 
 
Hemodynamical parameters include mean arterial pressure, MAP (mmHg) and cardiac output, 
CO (L/min). 
 
Paper I 
 
At 5-min intervals, heart rate, MAP, right atrial pressure, mean pulmonary arterial pressure, 
and the pulmonary arterial occlusion pressure (PAOP) were measured using a Hewlett 
Packard 78304 (Santa Clara, CA). Cardiac output was measured in duplicate using iced saline 
thermodilution (Cardiac Output Computer, Baxter, Irvine, CA).  
 
Paper II 
 
Monitoring consisted of electrocardiography (ECG), pulse oximetry and noninvasive arterial 
blood pressure measurements (Cuff).  
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Paper III 
 
Hemodynamic supervision was maintained by electrocardiography, pulsoximetry and non 
invasive blood pressure measurements (Cuff) (Propaq 104, Systems Inc., Beaverton, OR). 
 
Paper IV 
 
The blood pressure was monitored by a non invasive digital blood pressure monitor 
(Omron®, Kyoto, Japan) at time points 0, 15 and 120 minutes, through a cuff. 
 
Blood 
 
Blood properties include haemoglobin concentration, Hb (g/dL), plasma volume, PV (ml), 
hematocrit, Hct and red cell count, RBC.  
 
Paper 1 
 
Hct and Hb were measured using 1-ml arterial samples (HemaVet 850, CDC Technologies, 
Oxford, CT). PV at baseline was measured using indocyanine green (ICG; Akorn Inc., 
Buffalo Grove, IL). 
 
Paper II 
 
Cannulae were inserted into one radial artery and the antecubital veins in both arms. The arm 
with both arterial and venous access was used for blood sampling and the other side for the 
infusion of fluid. Arterial and venous blood were simultaneously sampled at precisely timed 
intervals for analysis of Hb and Hct, using a Technicon H2 (Bayer, Tarrytown, NY) which 
determines Hb by colorimetry at 546 nm. 
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Paper III 
 
Intravenous cannulas were placed in antecubital veins on each side. One cannula was used for 
blood sampling, the other for fluid infusion. Blood samples (4 mls) were taken every five 
minutes during the first 120 min, and thereafter the sampling rate was every 10 min until the 
end of the experiment at 240 min. Hb and RBC were analyzed using a Coulter Counter STKS 
device (Coulter Electronics, Hialeah, FL, USA).  
 
Paper IV 
 
Blood samples were taken at time points 0, 10, 15, 20, 30, 45, 60, 75, 90, 120 minutes. Total 
study time was two hours. Haemoglobin and haematocrit were measured by fluorescent flow 
cytometry (XE-5000, SYSMEX,  Stockholm, Sweden). 
 
 Urine 
 
Paper I 
 
One day before each experiment a urinary bladder catheter was inserted into the sheep 
(Sherwood Medical, St. Louis, MO). Urinary volumes were measured every 5 min. 
 
Paper III 
 
A standard bladder catheter, connected to a drip counter to monitor urine excretion 
continuously, was inserted before the experiment (Sherwood Medical, St Louis, MO). 
 
Paper IV 
 
The urinary bladder was scanned at 0, 15 and 120 min by an ultrasonic scanner BVI-3000 
(Bladderscan®, Allytec, Stockholm, Sweden). The volunteers were allowed to void during the 
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experiments. The amount of voided urine was estimated. At the end of the experiments the 
patients were once again weighed before and after voiding. 
 
Plasma content 
 
Plasma content includes glucose (mmol/ml) and total plasma protein, Prot (g(dL). 
 
Paper I 
 
Blood was withdrawn every hour for measurements of Prot by refractometry (Shuco, Tokyo, 
Japan) and of serum colloid osmotic pressure (4100 Colloid Osmometer, Wescor, Logan, 
UT). 
 
Paper IV 
 
Glucose concentration was analyzed by a photometrical method (Roche Diagnostics, Modular 
P-800, Indianapolis, USA). 
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6 FLUID THERAPY 
 
 
 
A desert tree in Tenerife, Canary Islands [37] 
 
 
6.1 INTRODUCTION 
 
What exactly do we mean when we talk about fluid therapy? If we consider a plant, we know 
more or less instinctively that if we supply too little water, the plant will dry out and finally 
die (restricted diet). If we supply too much, the plant may drown and ultimately die (generous 
diet). However, we also know that a plant does not need an exact amount of water every day. 
We just pour some water regularly onto the plant and it seems to adapt to our care-giving. As 
long as it survives, we conclude that we are doing the right thing. Would a patient in intensive 
care for example, accept this fluid strategy?  
 
The fluid balance in the human body is much more than considering the turnover of water, of 
course, and by far more complex than any fluid therapy of plants, restricted or generous. It is 
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also a matter of fluid content; ions, proteins, glucose etc that has to be “in balance” - the fluid 
homeostasis. 
 
Our body can compensate disturbances, by either adapting to this new “balance” or by other 
mechanisms that suppress the perturbation. 
 
What is the optimal fluid balance for an individual? Is it possible for a clinician to determine 
by a simple method a fluid strategy to obtain this optimum for any individual patient? And 
what are the end-points that the clinician should aim at? 
 
6.2 THE FLUIDS 
 
Crystalloid fluids 
 
Crystalloid fluids are solutions of small particles, containing both ions and non-ions. The 
colloid pressure contribution is zero, and such fluids thus contain only solutes that pass freely 
through the capillary membrane. 
 
In paper II, we used lactated Ringer’s solution (ionic content: Na+ 130 mM, Cl- 109 mM, 
Ca++ 3 mM, K+ 4 mM, acetate: 28 mM, pH 6.5, osmolality: 273 mOsm/l). 
 
In paper III, we used acetated Ringer’s solution, 25 ml/kg (ionic content: Na+ 130 mM, Cl- 
110 mM, Ca++ 2 mM, K+ 4 mM, lactate: 30 mM, pH 6, osmolality: 270 mOsm/litre).  
 
These solutions contain lactated or acetated ions for pH-buffering reasons. They are mildly 
hypotonic. Since acetate may be metabolized by all cells, in contrast to lactate which can be 
metabolized only in the kidney and liver, it might be more beneficial to use acetate in 
situations with poor circulation. However, no clinical study has yet showed any significant 
clinical difference between the solutions in a clinical setting [49]. 
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Colloid fluids 
 
Colloid fluids contain solutes that lead to an increase in oncotic pressure. They are mainly 
used for replacing lost blood and for goal directed protocols, and the risk of forming oedema 
is lower than it is when using crystalloid fluids, since they tend to allocate intravascularly. 
However, if there is a pathological situation with increased capillary leak, colloids might 
contribute even more to the formation of oedema. Furthermore, there is a trade off between 
replacing lost intravascular volume and overload of the circular system which might have 
detrimental effects on patients with cardiac failure. Colloids are also expensive and in major 
randomized clinical trials there are no differences in outcome between crystalloids and 
colloids [50-51].  
 
There are four main groups of colloid fluids; albumin solutions, starches, dextrans and 
gelatins.  
 
Colloids in general, are more expensive than crystalloids, and the most expensive colloid is 
the albumin solution [52]. The synthetic colloids can induce anaphylactoid reactions. Starches 
and dextrans may alter coagulation and renal function [20]. Dextrans may even cause severe 
anaphylactic reactions which can be prevented by giving low molecular sized dextran-122 
[53].  
 
Hypertonic fluids 
 
Combined solutions of hypertonic crystalloids and colloids are extensively used in several 
clinical settings [20].  
 
Hypertonic solutions, like colloid solutions, are mainly used to restore the plasma volume. 
Moreover, the hypertonic solution also promote urine output [54], increase of cardiac 
contractility and vasodilatation of the peripheral vasculature [55].  
 
                                                 
22 A solute containing small colloids (hapten), given some minutes before infusion of dextran to prevent the 
anaphylactic reaction. 
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However, hypertonic solutions with or without a colloid may cause some adverse effects such 
as hypernatremia, but the high level of sodium is transient. One major concern however, is if 
these solutions are given too rapidly, they may worsen an acute bleeding in a trauma situation 
[56]. However, they might have anti inflammatory properties that might be beneficial.   
 
Glucose solutions 
 
Glucose solutions, as used in Paper IV, are commonly used, especially during surgery of 
hypoglycaemic patients. Furthermore, infusion of a glucose solution provides an energy store 
that may benefit patients undergoing thoracic surgery. These solutions are also used post-
operatively and during post surgical rehabilitation in the ward. 
 
6.3 PER-OPERATIVE FLUID STRATEGY 
 
Fluid management is an important part of per-operative care, as a tool to keep patients stable 
regarding the circulation, oxygen delivery, organ perfusion, acid-base balance and the overall 
fluid homeostasis.  
 
Thus, the clinician will aim at some important end-points during per-operative fluid 
management:  
 
1. The organs and tissues should be well perfused, especially vital organs such as the heart,     
liver, brain and kidneys 
2. The blood volume should at least remain at baseline 
3. Cardiac output should be optimal 
4. Blood pressure should be kept stable 
5. Urine output should be relevant in comparison to the fluid balance 
6. Oxygen delivery and consumption should be optimised 
 
These end-points are commonly used in a conventional approach to per-operative fluid 
therapy based on visible clinical signs and laboratory values. Due to the high level of 
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complexity of the circulation system, the clinician is referred to endpoints such as 
measurement of blood pressure, urinary output and heart rate but would probably be better off 
if clinical decisions could be based on a more accurate understanding of the underlying fluid 
balance [20]. 
 
Furthermore, the final therapy will depend on the pathophysiology and type of surgery. Heart 
failure patients [57], severely burned patients [58] or neurosurgical patients [59], for example, 
may require that other considerations overrule the conventional approach.  
 
6.4 OPTIMIZING CARDIAC OUTPUT 
 
If cardiac output (CO) is monitored, by an oesophageal Doppler for example, the goal 
directed fluid strategy aims to increase the cardiac filling until the heart muscle does not 
respond with increased work any longer. This limit is hypothetical and based on the 
assumption that an intravenous volume load will increase the filling of the heart, which then 
increases cardiac output (Starling forces). If a patient receives fluid, and CO increases, then 
this patient is a “responder” – he or she responds adequate to the fluid infusion. If the patient 
does not respond to the load, then the patient is considered to already be optimized and a 
“non-responder” [60-62]. 
 
A non-responder may increase the cardiac filling due to an intravenous fluid infusion; 
however, the heart will no longer be able to pump out the fluid in the same rate. In this 
situation, any more administrated fluid is superfluous, and will eventually cause cardiac 
failure with subsequent interstitium oedemas.  
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Figure 16. Illustration of a goal-directed fluid administration, when CO (= SV · HR ) and 
cardiac filling (LVEDV) are monitored. In this example, the two first infusions 
A and B shows a response while C and D no longer give any response [62]. 
 
6.5 ADVERSE EFFECTS OF FLUID THERAPY 
 
Regardless of what endpoint is chosen for per-operative fluid management there is an 
inevitable movement of protein-free fluid to peripheral, functional or non-functional parts of 
the body at least when using crystalloids.  
 
Clinicians observed a phenomenon in the army hospitals at Da Nang during the Vietnam war: 
“wet lung syndrome” or the “Da Nang lung”. This was due to a new fluid regimen, used to 
treat patients suffering from trauma, in which an exaggerated use of crystalloids was used, 
together with packed red blood cells.  
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1st Lt. Francis Curtin, Bellingham, Washington, MC, gives 
plasma to an unidentified wounded American soldier somewhere 
in Korea. 7 Aug 1950. From The Office of Medical History, U.S. 
Army Medical Department and Army Medical Command. 
 
This new treatment showed a better outcome than the fluid regimen used in the Korean War, 
where the extensive use of colloids and plasma sometimes resulted in renal failure [63]. Thus, 
the large amounts of crystalloids prevented renal failure in Vietnam, but instead caused 
pulmonary oedema, later understood to be caused by Acute respiratory distress syndrome 
(ARDS) [64]. The improved survival rate in Vietnam could, however, could have been 
attributed to better field care, rapid evacuation and early surgical stabilisation and not the 
fluid treatment per se. 
 
The fluid resuscitation strategy from Vietnam, originally based on ideas of Shires et al. [65] 
later found its way to civilian practice, which meant that practitioners started to give large 
amounts of crystalloids to ordinary elective surgical cases in the ORs23 [66].  
 
Peripheral upload of fluid 
 
Fluid shifting out of the vasculature is still an apparent problem during anaesthesia and 
surgery. This occurs intra-operatively as well as during several days postoperatively.  
 
Due to the nature of the capillary endothelial wall it is inevitable that protein-poor fluid will 
move to interstitial tissues. Patients can accumulate such fluid extensively, and increase their 
                                                 
23 Operating rooms 
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postoperative weight and, increases in morbidity and mortality [67] have been attributed to 
this increase in weight. These side-effects can be cardiopulmonary complications, slower 
tissue healing and a general increased hospital stay [6, 68].  
 
Moreover, when the endothelium is damaged, as is the case in septicaemia, the leakage of 
protein-rich fluid may also increase. There is an overwhelming consensus that excessive 
peripheral fluid accumulation that causes weight-gain postoperatively is detrimental [69].  
 
Fluid shifting is also particularly exaggerated during pathological conditions and if addressed 
wrongly by giving large amounts of crystalloids this could be detrimental to the patient [67, 
69].  
 
A rational approach of fluid therapy was suggested by Chappell et al.[70]. A healthy vascular 
endothelium is coated by the endothelial glycocalyx, which is considered to play an important 
role in the filtration process. During infusion, the function of glycocalyx may be altered due 
to the shear force of infusing fluid. The glycocalyx might be more permeable and allow more 
fluid to escape to the interstitium.  
 
 
 
 
 
 
 
 
 
 
Figure 17. The steadily increase of infusion volume during 
surgery (here cholecystectomies). By permission of 
Kathrine Holte. 
 
In addition to peripheral accumulation, and the forming of oedemas, fluid therapy may induce 
several other serious adverse effects if not used properly; hypertension, hyperchloremic 
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acidosis and renal failure are some of them [20].  Chappell and co workers suggest a moderate 
crystalloid fluid replacement in combination with a colloid replacement of lost blood. 
 
Conclusions 
 
Fluid therapy during the last ten years are moving back to protocols according to the original 
researchers findings in the 1930s – the body strives to maintain salt and water when it is 
stressed. Consequently, hospitals are abandoning the aggressive crystalloid period and going 
for more restrictive protocols [6, 70-71]. 
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7 MATHEMATICAL MODELLING OF BODY FLUIDS 
 
 
 
The image shows the result of a computation of a dispersion-convection PDE, 
based on a fractal tree representing the vascular system. A solute is injected in 
the peripheral veins at t = 3 s, and disperses by diffusion and convection 
through the cardiovascular tree. This model is based on the work by 
Dokoumetzidis et al. [72] 
 
 
7.1 INTRODUCTION 
 
The use of mathematics in describing basic principles of nature plays a fundamental role for 
mankind when coming to understanding or explaining a certain phenomena predicting future 
phenomen. Statistics, one of many mathematical disciplines, are extensively used in clinical 
science. However, other areas such as bioinformatics, pk/pd-modelling, computational 
genomics, biophysics have been added to the increasing field of science. They are commonly 
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addressed as the biomathematical fields. It is worth mentioning a few mathematical 
concepts/disciplines within the field of modelling body fluids and fluid therapy. 
 
7.2 OVERVIEW  
 
Compartmental dynamic system (CDS) 
 
In this section I will refer to a several disciplines, using the same concepts, as CDS. A CDS 
consists of a finite number of units, called compartments. The basic compartment contains a 
finite amount of an agent, which is considered to be evenly distributed within the 
compartment (well-stirred). There may be flows, transporting the agents from or into the 
compartment, as long as the mass conservation holds for the CDS. A system that is both 
inflow and outflow-closed is said to be a closed system.  
 
 
Figure 18. An example of a CDS.  
 
CDC provides an intuitive approach of understanding and analysing otherwise complex 
dynamical systems and the mathematics is well established (compartmental analysis) [73].  
 
 
Pharmacokinetics (PK) 
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The word “Pharmacokinetic” was established by F. H. Dost, a Professor in Germany who 
defined it as “the science of the quantitative analysis between organisms and drug” [74]. By 
pharmacokinetic modelling and computation, characteristic properties and the activity of a 
drug may be quantified in their ability of binding to tissues, proteins, fluids etc, the volume of 
distribution, half-life of concentration, rate of metabolism, excretion rate and much more [74-
75].  
 
Physiologically based pharmacokinetics (PBPK) 
 
The pharmacokinetic concepts may be expanded into physiologic mathematical models, 
where the drug interacts in relation to blood flows, organs and tissue volumes [76]. This 
methodology is referred as PBPK.  
 
Lumped element models 
 
Also called lumped parameter models. This methodology, in physiological contexts, 
simplifies hydrodynamics into a CDS model with expandable volumes. Now, flows, fluidity 
and resistance govern the flows between compartments [77-78]. They are also referred as 
electrical analogues, since they may be transformed in to electrical circuits [79]. They can be 
further extended also to take into account the dynamics of osmolar content [32].  
 
Computation fluid dynamics 
 
This computational research field, within fluid dynamics, basically deals with the Navier-
Stokes equation for arbitrary boundary conditions. These boundaries may represent virtually 
any part of the body exposed by a flow [80]. Because of the complexity of the mechanisms 
that governs flow of fluids, the computational effort and the build up of a valid domain, may 
limit the usefulness for larger regions. Though, there exists simplified models with fluid 
dynamical elements [36]. 
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Full-body simulators 
 
Some full-body simulator of the body fluid dynamics have been developed during the years 
for the purpose of education [81] and research [32, 82].  
 
Control concepts 
 
The use of control theory, the mathematical/engineering discipline dealing with dynamical 
systems, is obvious since a wide range of biological processes, consisting of feedback 
mechanisms including receptors, hormones and other regulating stimulators may be described 
as open or closed loop systems. The methodology offers a compact approach of describing 
such systems with a few set of parameters. This should be compared with the lumped element 
method, where complex physiological systems virtually need a large number of parameters to 
correlate with empirical data adequately [83]. 
 
7.3 FLUID KINETICS 
 
Fluid kinetics, or volume kinetic, analysis is a method to compute body fluid dynamics due to 
various clinical perturbation of the full body fluid distribution. The advantage of using this 
fairly simplistic approach, of an otherwise complex physiological mechanism, is that only one 
tracer is needed – haemoglobin.  
 
By using linear models, we may quantify the full-body volume effect of fluid administration 
through a finite set of parameters. Compared to pharmacokinetics, fluid kinetics examines the 
volume effect of various fluids. 
 
 
 
The basics 
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Fluid is administrated either intravenously by ki [ml/min] or per orally by ko [ml/min]. In the 
latter case, the fluid must pass an intermediate compartment Vo before entering the central 
fluid space V1. V1 [ml] is the estimated initial distribution volume of haemoglobin which have 
the quantity XHb [mmol]. From V1, the fluid is eliminated by the rate constant kr [ml/min] and 
by the basal elimination kb [ml/min]. Furthermore, V1 is communicating with the peripheral 
fluid space V2 by the parameter kt. In the presence of osmotic gradients between the cellular 
and interstitial fluid space, water is exchanged by the rate kc [ml/min]. 
 
Figure 19. Kinetic pathway of fluid 
 
 
In fluid kinetics, we make use of dilution rather than concentration. The relative change, or 
the dilution, is dimensionless and defined as: 
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Assuming vp = v1, and disregarding any osmotic imbalances, the kinetic equations sums up 
into a system of ordinary differential equations: 
 
V1 V2 
Vc kc 
ki 
kr + kb 
ko 
Vo 
1/To 
kt 
v1 
Haemoglobin 
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the two volume model with intravenous administration of isotonic fluid. The parameters kt, 
V1, V2, kr and kb are estimated by nonlinear minimization routines after solving the system 
either analytically or numerically. 
 
Amount model 
 
By substituting v1 – V1 by a1 and v2 – V2 by a2, we may rewrite the differential equations as: 
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If the classical two-volume model fails to identify, or estimate the distribution volume of the 
peripheral space V2, the differential equations will collapse due to the division by V2. By 
setting *1,22, akak tt ⋅=⋅  we get the system: 
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If we violate previous assumptions from volume kinetics, of the scaling between V1 and V2, 
letting a* = a2, a new bi-exponential model would take form. This model will converge for 
Mathematical modelling of clinical applications in fluid therapy 61
both one and two-volume models [93] but with the loss of information about the scales 
between a1 and a2 and the translation of kt,1 into kt. Still, this model has the advantage of not 
dividing the fluid kinetic models into one- and two volume models. This model was used in 
paper II. 
 
The concepts of fluid kinetics may be extended further to also take into account osmotic 
shifts, as in paper IV. 
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8 THESIS SUMMARY 
 
 
 
Σ 
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8.1 PAPER I 
 
 
Background 
 
After hemorrhage, blood volume is partially restored by transcapillary refill, a process of 
spontaneous compensatory intravascular volume expansion [48, 84] that we hypothesized 
would be inhibited by anesthesia.  
 
Methods 
 
Six chronically instrumented sheep were subjected to four randomly ordered experiments 
while conscious or during anesthesia with isoflurane. After plasma volume measurement 
(indocyanine green), 15% or 45% of the blood volume was withdrawn. To quantify 
transcapillary refill, mass balance and kinetic calculations utilized repeated measurements of 
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haemoglobin concentration, assuming that transcapillary refill would dilute haemoglobin 
concentration. 
 
Ethical considerations 
 
The protocol was approved by the institutional Animal Care and Use Committee (IACUC) 
and conformed to guidelines for the care of laboratory animals. 
 
Modelling 
 
A system of ordinary differential equations, based on the Starling mechanism, was derived 
quantifying the contributions of hydrostatic and oncotic forces to the capillary refill on a whole-
body level: 
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where Vp and Vi  is plasma and interstitial fluid volumes, respectively, Ap and Ai is the   
amount of colloidal protein in the plasma and interstitial fluid volumes, t is time (min), kt is an 
oncotic flow coefficient (ml2 g-1 min-1), kp is a pressure-compliance coefficient (min-1), 
ka is a colloidal flow coefficient (ml min-1) and Ra is a colloidal turn-over rate coefficient (ml 
min-1). 
 
The four unknown parameters in the model (kt, kp, ka, and Ra) were estimated for each 
experiment separately using Matlab 6.51 (MathWorks, Natick, MA). Input parameters were the 
measured plasma volume (Vp) at baseline, initial values for the amount of protein in the plasma 
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(Ap) and interstitial fluid volumes (Ai), in which the baseline interstitial fluid volume was 
approximated to be 15% of the body weight. The protein concentration at 180 min was used as 
Cp,0. The solution of the differential equations was then fitted to the plasma volume as indicated 
by the data on Hb dilution. 
 
Results 
 
All animals tolerated all 4 experiments well, except for one conscious sheep in which 
hypotensive hemorrhage was terminated because of a clotted pulmonary arterial catheter. 
 
After 15% hemorrhage, mean arterial blood pressure remained stable in both conscious and 
isoflurane-anesthetized sheep (normotensive hemorrhage) but decreased after 45% 
hemorrhage (hypotensive hemorrhage). After either normotensive or hypotensive 
hemorrhage, transcapillary refill occurred more rapidly during the first 40 min than during the 
next 140 min (p < 0.001). In conscious sheep, at 180 min, 57% and 42% of the bled volume 
had been restored after normotensive and hypotensive hemorrhage, respectively, in contrast to 
only 13% and 27% (p < 0.001) in isoflurane-anesthetized sheep.  
 
In 21 of 23 experiments, we could quantify the influences of hydrostatic and oncotic forces on 
transcapillary refill by kinetic analysis. In the remaining 2 experiments, data were too 
scattered to allow estimation of all 4 parameters. The result suggests that transcapillary refill 
reduced the intravascular colloid osmotic pressure by diluting the plasma protein 
concentration, which slowed further transcapillary refill. Using parameters derived from 
kinetic analysis, simulations illustrate that both the hydrostatic and colloid osmotic forces are 
weaker in the presence of isoflurane than in the awake state. 
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Figure 20. The transcapillary flows, as separated by the mathematical model. 
 
Conclusions 
 
We concluded that isoflurane inhibits transcapillary refill after both normotensive and 
hypotensive hemorrhage in sheep. 
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8.2 PAPER II 
 
 
 
Background 
 
Crystalloid fluids, such as lactated Ringer’s solution, are commonly used during anesthesia 
and surgery. When infused into the circulation, hemodilution occurs which correlates with the 
increase in plasma volume. Therefore, haemoglobin (Hb) changes have been used to indicate 
the plasma or blood volume over time [85-87] although the large-vessel: whole body 
hematocrit (Hct) ratio of 0.9 should be applied to correct for anticipated unequal distribution 
of the Hb molecules [87-90]. 
 
Since fluid can be assumed to distribute faster than molecules of any size, infused fluid is 
allocated to parts of the plasma volume and adjacent areas of the peripheral space that are 
easily perfused [91].  
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The conventional view suggests that infused crystalloid fluid is first distributed in the plasma 
volume and then, since the capillary permeability for fluid is very high, almost instantly 
equilibrates with the extracellular fluid space [92].  
 
Methods 
 
Fifteen volunteers received an IV infusion of 15 ml/kg of lactated Ringer’s solution during 10 
min. Simultaneous arterial and venous blood haemoglobin (Hb) samples were obtained and 
Hb concentrations measured.  
 
The arteriovenous (AV) difference in Hb dilution in the forearm was determined and a 
volume kinetic model [93] was fitted to the series of Hb concentrations in arterial and venous 
blood to quantify this effect. 
 
The kinetics of the IV infused fluid was modelled separately for each subject, using Matlab 
version 7.0.1 (Math Works, Notich, MA), whereby a nonlinear least-squares regression 
routine based on a modified Gauss-Newton method was repeated until none of the three 
unknown parameters (V1, kt, and kr) changed by more than 0.001 (0.1%) in each iteration. No 
correction was applied for the transit time for blood between the radial artery and the cubital 
vein since we believed this would be <10 s. 
 
Ethical considerations 
 
The study was approved by the Institutional Animal Care and Use Committee, University of 
Texas Medical Branch at Galveston, Texas, USA. 
 
One issue was the insertion of an arterial line. There is a slight possibility of complications. 
However, this was necessary because of the aim of comparing the arterial and venous Hb 
dilution (A-V difference). 
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Less than 200 ml of blood was drawn from each subject. A normal blood donor gives about 
400 ml of blood. 
   
Results 
 
The AV difference in plasma dilution was only positive during the infusion and for 2.5 min 
thereafter, which represents the period of net flow of fluid from plasma to tissue. Kinetic 
analysis showed that volume expansion of the peripheral fluid space began to decrease 14 min 
(arterial blood) and 20 min (venous blood) after the infusion ended.  
 
 
Figure 21. Example of an arterial-venous Hb data and model fit by a lumped 
parameter model of 10 compartments. 
 
 
Conclusions 
 
Distribution of lactated Ringer’s solution apparently occurs much faster in the forearm than in 
the body as a whole. Therefore, the AV difference in the arm does not accurately reflect the 
distribution of Ringer’s solutions or whole-body changes in plasma volume. 
 
The relatively slow whole-body distribution of lactated Ringer’s solution, which boosts the 
plasma volume expansion during and for up to 30 min after an infusion, is probably governed 
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by a joint effect of capillary permeability and differences in tissue perfusion between body 
regions. 
 
Analysis and observations relevant of the thesis 
 
 
In paper II, we refer to V1 and V2 as functional spaces and not physiological. But in the fluid 
kinetic section, we stated that vp = v1. The reason for this is because we assume that 
information of vp is lost when only considering the dilution of Vp. However, the coupling 
between V1 and Vp is clearly strong, because of the underlying assumption of Hb-dilution. 
Furthermore, we showed in this paper, for arterial samples, we got an almost 1:1 correlation 
between the Nadler-formula of Vp, and the computed central space V1, from arterial Hb-data. 
 
For a closed expandable compartment, with Hb as a dilution tracer, we found out that the 
plasma volume was given by: 
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If we apply this relationship onto the subjects, where the infusion time was 10 minutes, and 
the rate of infusion was 1.5 ml/min/kg of lactated Ringer´s solution, we may compute an 
estimation of the plasma volume. If we chose to correct the Hct by 0.9 and compute three 
values of Vp at t = 3, 6, 9. Then we may estimate the mean 
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and for this estimation we choose to put weights. Firstly, I make use of the arterial data. When 
comparing these results by the plasma volume predicted by Nadler et al., we find a 
convincing agreement (k = 1.05, p< 0.05, N=13). See Figure 22.  
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Figure 22. (Arterial data) Comparison of estimation of Vp from an crystalloid infusion (y-
axis) and an empirical formula developed by Nadler et al. (x-axis).  
 
 
Now, if we redo the computation on the venous side, we will see that our model looses 
agreement with the Nadler formula. See Figure 23. 
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Figure 23. (Venous data) Comparison of estimation of Vp from an crystalloid infusion (y-
axis) and an empirical formula developed by Nadler et al. (x-axis). 
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If we compare Figure 22 and Figure 23, we can see a more pronounced variability of the 
venous sampling.  
 
From this we may conclude that arterial Hb seems to reflect the plasma volume expansion 
even if considered as a closed volume, and at least initially during infusion. Furthermore, in 
this paper, we concluded that the sampling curves showed similar profiles. Despite the 
similarities, the venous data overestimates the plasma volume grossly according to figure 8. 
When applying a fluid kinetic model as in paper II, these estimations were thus improved 
significantly (arterial: k = 1.00, r = 0.7, p < 0.001; venous: k = 1.37, r = 0.69, p < 0.01). 
 
However, this relationship is not usually explored, since sampling is hampered by the 
requirement of an arterial line which is considered to be an invasive operation that can cause 
damage to the vessel. When sampling venous data, we analyze only locally mixed blood that 
previously went through a filtration process through the capillary bed. Interstitial fluid spaces 
in the lungs probably become expanded quickly and easily, whereas some of the lactated 
Ringer’s solution might not even reach the interstitium of poorly perfused areas with resting 
muscle. The Hb changes of the arterial blood represent the sum of all such occurrences, while 
the venous blood reflects the arterial blood including the local tissue effects. 
 
Therefore, further experiments has to be carried out, in order to find out during what 
circumstances this holds for and how the clinicians may compute the blood volume using only 
Hb as a tracer.  
 
The fluid homeostasis mainly (or ideally) depends on the daily intake of salt and water. 
During hypervolemia, due to release of ANP and the increased filtration pressure, urine 
output will increase significantly (see Figure 8). On the other hand, during hypovolemia, the 
basal diuresis will decline and eventually, during hypovolemic shock, it may be blunted.  
 
During fluid therapy, or as a result of a wide range of different pathological states, the fluid 
homeostasis will shift its baseline (steady state). That leads us to the question: would it be 
possible to analyze fluid distribution using math models when baselines are shifting due to 
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differences in hydration levels? Can this be done by giving our patients small quick boluses to 
find out their responses? 
 
Considering this trial where the subjects were not allowed to drink or eat the day before the 
experiments, obviously, they were to some degree dehydrated before they received iv fluids. 
 
By examining the results, the fluid infusion seemed to change their previous steady state. As 
we can see in Figure 24, the infusion even caused three of the subjects to drop their plasma 
volumes.  
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Figure 24.  Left: Spaghetti-plot of dilution (thin lines) and mean (thick line) (arterial data). 
Right: Two subjects chosen. Solid line represents arterial dilution and dashed 
line venous dilution. 
 
As an example of the modelling process, we will go through the process step by step. 
 
1. Fluid kinetic model 
 
First, we consider the fluid kinetic model: 
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where kr = 0 if a1 < 0. In this system of ODE, we transformed the dilution and the parameter kt 
(see section Fluid kinetics) by 
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subsequently, the model has 5 parameters to be considered: kp (min-1), V1 (ml), kr (min-1), µ, 
kb (ml/min). 
 
2. Discrimination of models 
 
For this example, we choose to investigate the residual sum of squares, RSS, and perform a F-
test as an estimation of discrimination between rival models [94]. Six rivaling models were 
chosen 
 
Model kp  V1  kr µ kb
1 X  X  X  X  X
2 X  X  X  X  0
3 X  X  X  1  X
4 X  X  X  1  0
5 0  X  X  0  X
6 0  X  X  0  0
 
Table 3. Discrimination test of six models where X is to be estimated 
 
Choosing subject 2, venous data, (see figure 25, right plot), we get the result: 
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 Table 4. Parameter estimation of six models. σ is the estimated standard deviation of each 
parameter.  
 
Next step was to compute the residuals and perform the F-test: 
 
Test (T-N) RSST RSSN F-test
1-2 0.002878 0.00273 0
1-3 0.002878 0.002609 0
1-4 0.002878 0.002589 0
1-5 0.002878 0.003312 0
1-6 0.002878 0.010937 1
2-4 0.00273 0.002589 0
2-6 0.00273 0.010937 1
3-4 0.002609 0.002589 0
3-5 0.002609 0.003312 0
3-6 0.002609 0.010937 1
4-6 0.002589 0.010937 1
5-6 0.003312 0.010937 1
 
Table 5. Residual sum of squares and the F-test. RSSN is residual sum of squares of the nested 
model N, which is tested against the model T with RSST. p = 0.05 was chosen as significance 
level in the F-test. 
 
The F-test suggests that model 6 were discriminated by all models. Moreover, test 1-N, 2-N 
and 3-N suggested that we did not get any significantly better fit by the T model. What are 
left are models 4 and 5. Looking closer at the estimates, and comparing the RSS, model 5 
gives an ambiguos estimate of kb, probably due to compensation of peripheral upload since it 
lacks the kt parameter. Hence, we conclude that for subject 2, model 4 would be the model to 
choose and it is likely that we may set µ = 1 and kb = 0.  
Model kp ±σ V1 ±σ kr ±σ µ ±σ kb ±σ
1 0.059 0.004 3575 753 0.0000 0.0078 0.52 0.12 2.6 2.5
2 0.040 0.007 3984 898 0.0073 0.0003 0.69 0.02 0 0
3 0.050 0.010 3775 852 0.0102 0.0026 1 1 0.8 2.0
4 0.048 0.011 3794 863 0.0121 0.0023 1 1 0 0
5 0 0 4537 1010 0.0555 0.0122 0 0 -19.8 5.1
6 0 0 5103 1055 0.0153 0.0031 0 0 0 0
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3. Extending the model 
 
As discussed earlier, it is clear that some of the subjects change their baseline during infusion, 
and it would be of clinical relevance of estimating this shift. Therefore, we added the 
parameter aref which allowed the model to adapt a new-steady state central volume. Normally, 
we would model this baseline shift by a sigmoid function. However, such approach would 
increase the number of parameters by two. Therefore we instead assumed that aref is the daily 
homeostatic baseline – the shift of baseline occurred during night before the experiment. Then 
aref is constant from t = 0. 
 
Subject aref,artery ±σ aref,vein ±σ F-test A F-test V
1 -128 83 -84 171 0 0
2 -228 89 -133 117 1 0
3 8 10 27 39 0 0
4 -80 45 65 79 1 0
5 49 6 131 25 0 0
6 -75 28 -83 36 1 1
7 79 4 163 12 1 0
8 -16 14 -53 38 0 0
9 -730 530 -829 1119 1 1
10 -45 15 -39 28 1 0
11 -6 32 2 30 0 0
12 63 9 44 64 1 0
13 -461 143 190 27 1 0
14 -76 47 -54 68 1 0
15 97 17 -293 714 1 0
 
Table 6.  
 
From Table 6, we show the result of the two models, the nested with aref = 0 and the full 
where aref was estimated. This was done both for arterial and venous samples. The F-test on 
arterial side suggested that for 5 of the subjects, it was more likely that aref,artery was zero. But 
for ten of the subjects, the F-test, with p = 0.05, showed a significance when adding aref,artery  
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to the model. However aref in general, seems to be more or less negligible -44 (-115 – 4)24 
when considering the small amount in millilitres the baseline actually was shifted, and with 
concerns about the general high standard deviation of the estimates. But what was of clinical 
relevance, was that three of the subjects seemed to be dehydrated before the infusion (-228, -
730, -461).  
 
On the venous side, only two of the subjects gained a significant improvement of using aref 
according to the F-test. Despite this weak indication of homeostatic baseline, we chose to 
present aref in paper II, for future work of finding a patient basal volume.   
 
 
 
                                                 
24 Median and range. These results differs slightly from those reported in paper II: -43 (-85 – 2), due to different 
optimization methods. 
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8.3 PAPER III 
 
 
Background 
 
There is an overwhelming consensus that excessive peripheral fluid accumulation, causing 
weight-gain postoperatively is detrimental [69]. Therefore, the clinician should benefit from 
being able to continuously monitor such fluid accumulation that sometimes occurs during per-
operative fluid therapy. In order to better understand the dynamics of hypervolemia and the 
renal response to excess fluid, we aimed at modelling plasma dilution and urinary output 
simultaneously in volunteers. 
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Methods 
   
Ten healthy female non-pregnant volunteers, aged 21-39 year (mean 29), with a bodyweight 
of 58-67 kg (mean 62.5 kg) participated. No oral fluid or food was allowed between midnight 
and completion of the experiment. The protocol included an infusion of acetated Ringer’s 
solution, 25 ml/kg over 30 minutes. Blood samples (4 ml) were taken every five minutes 
during the first 120 min, and thereafter the sampling rate was every 10 Min until the end of 
the experiment at 240 min. A standard bladder catheter connected to a drip counter to monitor 
urine excretion continuously was used. The data were analyzed by empirical calculations as 
well as a mathematical model. 
 
The kinetic model had eight unknown parameters: kt, kel, kb,σ, µ, Tu, T1, Te.  
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Estimates of the unknown parameters in the fluid space models were obtained by using the 
MatLab function fminsearch, which uses a simplex search method [95]. The differential 
equations were solved by the MatLab function dde23 suitable for delay differential equations 
[96].The minimizing function computed the equally weighed residuals of plasma volume 
expansion (a1) and urine output (uoutput). 
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Ethical considerations 
 
The study was approved by  Ethical Review Board of the Stockholm County. 
 
The total amount of blood drawn was less than 200 ml. One ethical concern was the insertion 
of a urinary catheter. There is an increased risk of infection in the urinary tract. Also, some 
mechanical damage to the urinary tract can be caused. Since this paper was to investigate the 
coupling between plasma volume expansion and urinary output, this device was crucial for 
the experiment. 
 
Results 
  
Maximum urinary output rate was found to be 19 (13 – 31) ml/min. The subjects were likely 
to accumulate three times as much of the infused fluid peripherally as centrally; 1/µ = 2.7 (2.0 
– 5.7). Elimination efficacy, Eeff, was 24 (5 – 35) and the basal elimination kb was 1.11 (0.28 – 
2.90). The total time delay Ttot of urinary output was estimated to 17 (11 - 31) min. 
 
Conclusions 
 
The experimental results showed a large variability in spite of a homogenous volunteer group. 
It was possible to compute the infusion amount, plasma dilution and simultaneous urinary 
output for each consecutive time-point and thereby the empirical peripheral fluid 
accumulation. The variability between individuals may be explained by differences in tissue 
and hormonal responses to fluid boluses which need to be further explored. 
 
Analysis and observations relevant to this thesis 
 
Elimination is modelled by [97-98]: 
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br kdilvkdt
dU +⋅= 1  
 
Where we require that kr = 0 if v1 < 0. In Figure 25, two subjects from this paper were chosen 
to illustrate the linearity. Subject 3, on the left figure, seem to fit the elimination model. 
However, subject 4, on the right figure, shows a more scattered appearance. 
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Figure 25. Left figure (subject 3): kr = 61.0 ml/min, kb = 3.2 ml/min, r = 0.67, p < 0.01. 
Right figure (subject 4): kr = 20.8 ml/min, kb = 0.2 ml/min, r = 0.09, p > 0.05. 
 
 
If we make an approach, that the renal output is more likely to be governed by an exponential 
model with a delay, the model would take the form 
 
( )11 Ttdilvk
b
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If we redo the computation of subject 4, in paper III by this model, setting the delay to T1 = 15 
min, we get the results, as plotted in Figure 26. 
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Figure 26. Subject 4 (exponential model): kel = 16.9, kb = 0.28 ml/min, r = 0.30, p < 0.01.  
 
From figure 14, we may conclude that subject 4 was more likely to follow the exponential 
delay elimination model. It is even more likely that the elimination as a function of plasma 
volume expansion should have a sigmoid appearance, as in Figure 27. 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Theoretical relationship between urine output and plasma volume expansion. 
 
 
During the modelling phase in this work, this relationship was examined by approximating 
the hypothetical urine output curve by this sigmoid function 
 
( )( )( )β−−⋅= )(tanh
2 cp
TtdilvcA
du
dU . 
Urine output 
ml/min 
Δvp 
Maximum urine output 
kb 
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An example of a test run is shown in Figure 28. 
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Figure 28. Fitting of urine output. The right figure shows the sigmoid fitted function. The 
dashed line illustrates an exponential equivalent model. 
 
From figure 26, we may conclude that our hypothesis agrees with data for this specific 
subject. However, the experiment was not from the beginning designed to fully examine this 
relationship why several of the subjects failed to identify all parameters needed. To examine 
the full range of this sigmoid curve, it was necessary to make the subjects both hypovolemic 
and give them drastically different infusion rates. This is by natural ethically questionable to 
do with volunteers and has to be performed in an animal model, preferably. Thus, the 
exponential equation worked well for this particular range of the sigmoid curve. 
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Figure 29. Elimination delays with a urinary catheter. 
 
 
Three different time delays were needed to fit all subjects in the same model. T1 reflects the 
delay of the renal response to hypervolemia. Te is probably due to a filling time within the 
bladder, before it reaches the top of catheter. Finally, Tu is the pathway from the tube, to the 
actual measurement, see Figure 29.  
 
As concluded in the discussion in Paper II, the complex and fairly long distribution process of 
crystalloids explains indirectly why we cannot be sure that V1 equals the baseline plasma 
volume. Furthermore, we concluded from the results that if we infuse a bolus of lactated 
Ringer’s solution into the plasma, some of the fluid will have left this physiological space 
even before the rest of it has become distributed throughout the entire plasma volume. This 
problem was dealt with in this paper, by inferring a bypass flow ratio σ that reflects a fast 
equilibration of fluid into the more easily perfused parts of the interstitium. In presence of 
such a fluid route, during infusion, the central fluid space might be overestimated.  
 
In summary, we concluded that in presence of simultaneously monitoring and computation of 
the size of central fluid space and urine output, the clinician would get an improved 
estimation of this peripheral accumulation and thereby be able to individualise the fluid 
therapy. 
 
T1 
Te 
Tu 
Bladder 
Catheter 
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8.4 PAPER IV 
 
 
 
 
Background 
 
The aim of this study was to compare two fluid administration routes, oral and intravenous 
administration in a young and an elderly group of healthy volunteers. We wanted to 
investigate differences in absorption of fluid, fluid distribution and its elimination in an 
elderly versus a young population.  
 
Our hypotheses were that there should be a lag time between orally and intravenously given 
fluids as regards to absorption. Older subjects will have a slower elimination of fluid and 
plasma glucose. Furthermore, orally given fluids will have a more prolonged volume effect. 
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Methods 
 
Twenty four volunteers were recruited by responding to advertisements and gave their written 
consent to participate in the study. The subjects were enrolled in age groups, a young group 
(age 18-25) and an elderly group (age 70-90). Exclusion criteria were pregnancy, dementia, 
diabetes, medication with diuretics, cardiac failure classified according to New York Heart 
Association (NYHA) III-IV and/or angiotensin converting enzyme inhibitors (ACEI). 
 
On separate occasions, the subjects in both groups were given a crystalloid 25 mg/ml glucose 
solution, either orally (ORAL) or intravenously (IV) in a crossover design with at least two 
weeks in between. 
 
On each occasion, the subjects got 7 ml/kg of the crystalloid solution during 15 minutes. 
During the ORAL experiment the fluid was administered in fifteen cups, where each cup 
represented 1/15 of the total amount.  In the IV group, the administration of fluid was 
administered by the aid of an infusion pump. 
 
Ethical considerations 
 
The study was approved by the Ethical Review Board in the Stockholm County. All patients 
were subject of intravenous cannulation, which may cause discomfort during perforation. 70 
ml of blood was drawn at total, which is considered to be a small amount. 
 
Results 
 
All subjects went through the experiments and there were no complications. The mean curves 
of glucose concentration and dilution of plasma volumes were plotted in Figure 30. 
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Figure 30. Shows the pooled data of glucose concentration and plasma dilution for the four 
groups. In Fig A, the group of elderly eliminates glucose slower than the 
younger group. In Fig B, the plasma dilution effect of the young group, given 
fluid orally, shows a reduction intially. Furthermore, the elimination of the 
plasma volume is more pronounced when fluid is given intravenously. 
 
The bioavailability crystalloid glucose solution was estimated to: 
 
Felderly = 0.65 (0.60 - 0.69) 
Fyoung = 0.70 (0.59 -0.94) 
 
And the bioavailability of the volume effect was estimated to be: 
 
Felderly = 1.06 ± 0.51  
Fyoung = 0.93 ± 0.59 
 
Data are presented as median and ranges. Also, the lag-time of glucose given orally was 
estimated to be 17 (8 – 25) min for the younger group and 18 (13 – 22) min for the elderly. 
For fluid, the lag-time was estimated to 29 (21 - 34) min for the younger and 25 (16 – 39) min 
for the elderly.  
 
Furthermore, we computed the half-life of raised glucose levels: 
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 t1/2 (min)
PO-young 3.8 (3.1 - 11.9)
IV-young 16.1 (14.8 - 23.0)
PO-elderly 30.5 (22.3 - 55.9)
IV-elderly 41.6 (23.8 - 54.6)
 
And finally, we computed the elimination efficacy of fluid: 
 
 Eeff (ml/min) 
PO-young 66.2 (13.6 - 106.3) 
IV-young 15.3 (6.4 - 49.2) 
PO-elderly 25.0 (8.0 - 44.5) 
IV-elderly 17.6 (8.0 - 46.6) 
 
Conclusions 
 
The data showed larger variations for the fluid kinetic calculations than for the glucose 
kinetics. As expected there was a significant lag time between orally and intravenously 
administered fluid, both for glucose and volume effect. Elderly subjects tended to eliminate 
glucose slower than younger as expected. Surprisingly, the younger subjects showed a more 
persistent tendency to keep the administered fluid than the elderly. 
 
Analysis and observations relevant to this thesis 
 
The glucose model could likely be improved by adding data for insulin and C-peptide. In 
summary, it was possible to use mathematical application to model the distribution of both 
oral and intravenous administration of fluid to young and old volunteers. The kinetic 
computations quantified the renal efficacy, volume effects, lag times, half-life of glucose, 
glucose clearance and base-line shifts of glucose. The bioavailability test of various fluids, 
stratifying for gender or age for example, may become a useful tool for future investigations 
in fluid therapy.   
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9 DISCUSSION AND CONCLUSION 
 
 
The aim of this thesis was to find mathematical applications to clinical problems. The 
clinicians work may be regarded as an open loop system, responding to a finite set of clinical 
parameters. These clinical assumptions may be modelled in some way, and eventually 
evaluated towards clinical signs and patient outcome. If the mathematical model, end-points 
and clinical observations give an adequate outcome for the patient, then we may conclude that 
theory and practice comes together. Furthermore, we may use the mathematical models to 
check that therapy aim towards clinical goals. 
 
Extending this conclusion further, we may in the future develop closed loop systems, where 
fluid is administered solely by an autopilot – in the same manner as ventilators or target 
control infusion for drugs (TCI).  
 
This thesis has shown that it is possible to use mathematical models to solve pertinent clinical 
problems, or at least quantify clinically useful parameters from the full-body effects induced 
by fluid therapy or bleeding. 
 
Though, there are several weaknesses identified. One major problem is the lack of relevant 
data to enhance the models (ions, hormones, cardiac output, oncotic pressure etc). Another 
weakness is the surprisingly large variability of Hb-data. In the appendix, I show an example 
of an ad hoc method to compare Hb data between the studies II - IV. This computation gives 
us a hint in how the quality of Hb data may differ between the studies. Interestingly, the group 
of elderly showed a more scattered behaviour than the young group (P < 0.05, t-test, unpaired) 
though they belonged to the same study (IV). These biases are probably a combined effect of 
differences in vein constitution, the technique of the clinician and presumable differences in 
coagulation factors. Furthermore, the use of iterative sampling of haemoglobin invasively is 
not clinically feasible. The need of an accurate and reliable non-invasive monitor of Hb is 
therefore essential for the future. 
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Furthermore, we need to develop devices that continuously monitor urine output in a non-
invasive fashion without interfering with surgical procedures. With these two devices, the 
clinician would know more precisely about the fluid shifts within the body, and be able to 
detect any peripheral upload. 
 
Moreover, during the modelling processes in this thesis, a number of simulators were 
developed in order to validate or examine hypothesis, from microvascular to full-body 
simulators. One problem of building such simulators, are the great number of parameters that 
are needed to fully explain perturbations of fluid homeostasis during fluid infusion. If models 
get too complicated they will not benefit clinicians in daily practice. 
Still: we do need realistic simulators for the future, for research and education. By the 
incremental growing knowledge in fluid therapy, mathematical modelling of full-body effects 
as well as isolated microvascular processes, through pre-clinical research, faster computers 
etc, full-body simulators will become more interesting tools. 
 
My final conclusion is that mathematical modelling of clinical applications improves the 
understanding of fluid therapy. It is possible to continuously model fluid behaviour in the 
body as seen in Papers II-III particularly. This should enhance the understanding of 
accumulating oedema in the body which is an apparent problem for all clinicians. Current 
research in the last decade focus on rigid or goal directed protocols which may be closer to 
the truth than previous standard of care regimes. They can, however, never exactly, reveal the 
fluid distribution at every time point. This can be done by the help of mathematical models 
which should move this area of research substantially forward.   
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10 APPENDIX 
 
 
Variability and quality of Hb data 
 
 
Suppose we knew the error-free Hb distribution ΩHb(t). Then, we measure Hb values as Θ = 
{θ1(t1), θ2(t2), ... θN(tN)}.  
 
Firstly, we define the integral Rθ to quantify the absolute difference between observed Hb and 
the real Hb: 
 
Rθ = ( ) ( )∫ −ΩN
t
t
Hb dttft
1
θ  
 
where  ( ) ( ) 1
1
1 , +
+
+ ≤≤−
−⋅−+= ii
ii
i
iii ttttt
tt
tf θθθθ  
 
Then we define: 
 
ρq = 
( )∫ ΩN
t
t
Hb dtt
R
1
θ  
Thus, we normalize Rθ. 
 
There are many choices of approximating ΩHb(t). One way is to compute the dilution from 
θ1(t1) to θ1(tN) and fit a kinetic model. However, a more general way, which can be applied 
directly onto the observed Hb, is by smoothing the data.   
 
Mathematical modelling of clinical applications in fluid therapy 95
We may for example use weighted moving average WMA, with n = 5. Then, if we choose a 
typical monoexponential solution to a kinetic problem, and smooth the data J times. 
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Figure 31. Left: An underlying exponential function (thick line), normal distributed errors 
(diamonds, STD=0.15) and smoothing curves for J = 5, 10, 20, 30, 40 (thin lines). Right: The 
cumulated error as a function of the number of smoothing runs by WMA. 
 
From figure 16, for this specific run, J = 8 gave the best fit of the underlying distribution. 
Approximating ΩHb(t) by ΔJΘ, where ΔJ is the smoothing operator, applied J times, and 
moreover, if we approximate the integrals by trapezoidal method, we finally get: 
 
( )
( )ΘΔ
Θ−ΘΔ=
J
JJ
q trapz
trapzρ  
 
Without formalizing this mathematics any further, we will give numerical examples of the 
studies conducted in the thesis, using J = 3, n = 5 and computing mean and standard deviation, 
we get the result: 
 
     4.5 ± 0.5 (artery data, work II) 
     6.2 ± 2.7 (vein data, work II) 
     6.7 ± 1.4 (vein data, work III) 
7.6 ± 2.9 (vein data, work IV, young) 
9.4 ± 3.1 (vein data, work IV, old)  
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